DK3565551T3 - Fremgangsmåder til behandling af bakterielle infektioner med en kombination af vaborbactam og meropenem - Google Patents

Fremgangsmåder til behandling af bakterielle infektioner med en kombination af vaborbactam og meropenem Download PDF

Info

Publication number
DK3565551T3
DK3565551T3 DK18735813.0T DK18735813T DK3565551T3 DK 3565551 T3 DK3565551 T3 DK 3565551T3 DK 18735813 T DK18735813 T DK 18735813T DK 3565551 T3 DK3565551 T3 DK 3565551T3
Authority
DK
Denmark
Prior art keywords
meropenm
vaborbactam
methods
combination
bacterial infections
Prior art date
Application number
DK18735813.0T
Other languages
Danish (da)
English (en)
Inventor
Jeffrey S Loutit
Michael N Dudley
Elizabeth E Morgan
Karen Fusaro
David C Griffith
Olga Lomovskaya
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62791302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3565551(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Application granted granted Critical
Publication of DK3565551T3 publication Critical patent/DK3565551T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK18735813.0T 2017-01-09 2018-01-08 Fremgangsmåder til behandling af bakterielle infektioner med en kombination af vaborbactam og meropenem DK3565551T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444238P 2017-01-09 2017-01-09
US201762513936P 2017-06-01 2017-06-01
PCT/US2018/012839 WO2018129479A1 (en) 2017-01-09 2018-01-08 Methods of treating bacterial infections

Publications (1)

Publication Number Publication Date
DK3565551T3 true DK3565551T3 (da) 2024-06-17

Family

ID=62791302

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18735813.0T DK3565551T3 (da) 2017-01-09 2018-01-08 Fremgangsmåder til behandling af bakterielle infektioner med en kombination af vaborbactam og meropenem

Country Status (21)

Country Link
US (1) US12478606B2 (enExample)
EP (2) EP4212157A1 (enExample)
JP (2) JP7436206B2 (enExample)
KR (2) KR102768209B1 (enExample)
CN (1) CN110402139A (enExample)
AU (1) AU2018205327B2 (enExample)
BR (1) BR112019014089A2 (enExample)
CA (1) CA3048650A1 (enExample)
CL (2) CL2019001918A1 (enExample)
CO (1) CO2019008575A2 (enExample)
DK (1) DK3565551T3 (enExample)
ES (1) ES2979266T3 (enExample)
FI (1) FI3565551T3 (enExample)
HU (1) HUE066805T2 (enExample)
MX (2) MX390529B (enExample)
NZ (1) NZ755141A (enExample)
PH (1) PH12019501606A1 (enExample)
PL (1) PL3565551T3 (enExample)
PT (1) PT3565551T (enExample)
SG (1) SG11201906226YA (enExample)
WO (1) WO2018129479A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478606B2 (en) 2017-01-09 2025-11-25 Melinta Subsidiary Corp. Methods of treating bacterial infections
AU2018345317B2 (en) * 2017-10-03 2024-10-24 Melinta Therapeutics, Inc. Methods of treating bacterial infections
WO2022026993A1 (en) * 2020-07-27 2022-02-03 Northwestern University Antimicrobial choice algorithm for urinary tract infections
CN117940127A (zh) * 2022-07-05 2024-04-26 塞戈瑞·弗拉基米罗维奇·西多连科 治疗多种耐药细菌感染的制剂
WO2024018372A2 (en) * 2022-07-20 2024-01-25 Sri Sathya Sai Institute Of Higher Learning A machine learning platform for predicting uropathogens and their resistance for prescribing suitable urinary infection therapy
JP2026517813A (ja) * 2023-05-02 2026-06-02 シプラ・リミテッド 医薬配合剤及び抗菌剤を含むその組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN105393011A (zh) * 2013-05-15 2016-03-09 舍弗勒技术股份两合公司 减少阻力的离合器板
WO2016172208A1 (en) 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
US12478606B2 (en) 2017-01-09 2025-11-25 Melinta Subsidiary Corp. Methods of treating bacterial infections

Also Published As

Publication number Publication date
MX2019008281A (es) 2019-12-02
FI3565551T3 (fi) 2024-06-18
KR20240133785A (ko) 2024-09-04
CO2019008575A2 (es) 2019-08-30
EP3565551A1 (en) 2019-11-13
KR102768209B1 (ko) 2025-02-18
US20190336475A1 (en) 2019-11-07
EP3565551B1 (en) 2024-03-20
PH12019501606A1 (en) 2020-06-15
MX2022001704A (es) 2022-03-11
WO2018129479A1 (en) 2018-07-12
SG11201906226YA (en) 2019-08-27
CL2020001886A1 (es) 2020-12-18
CN110402139A (zh) 2019-11-01
JP2023012538A (ja) 2023-01-25
EP4212157A1 (en) 2023-07-19
US12478606B2 (en) 2025-11-25
KR20190104385A (ko) 2019-09-09
CL2019001918A1 (es) 2020-02-14
EP3565551A4 (en) 2020-09-23
ES2979266T3 (es) 2024-09-25
PT3565551T (pt) 2024-06-14
JP2020504154A (ja) 2020-02-06
BR112019014089A2 (pt) 2020-02-04
JP7436206B2 (ja) 2024-02-21
AU2018205327B2 (en) 2023-11-30
AU2018205327A1 (en) 2019-07-25
PL3565551T3 (pl) 2024-09-23
CA3048650A1 (en) 2018-07-12
NZ755141A (en) 2023-01-27
HUE066805T2 (hu) 2024-09-28
MX390529B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
DK3697405T3 (da) Ny mek-inhibitor til behandlingen af virale og bakterielle infektioner
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3337549T3 (da) Kateteranordninger med ventiler og tilhørende fremgangsmåder.
DK4169491T3 (da) Indretninger og fremgangsmåde til behandling af bruxisme
DK3455978T3 (da) Multi-underbærebølge-fremgangsmåde og indretning med flere numerologier
DK3291679T3 (da) Ændring af mikrobielle populationer og modificering af mikrobiota
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
IL246678A0 (en) Azepane derivatives and methods of treating hepatitis b infections
DK3704227T3 (da) Sammensætning og fremgangsmåde
DK3220741T3 (da) Sammensætning og kits til hæmning af patogen mikrobiel infektion og fremgangsmåder til anvendelse af samme
DK3269809T3 (da) MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
DK3227237T3 (da) Indretning og anvendelse deraf til uv-bearbejdning af fluider
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3558280T3 (da) Forebyggelse og behandling af migræne
DK3619362T3 (da) Forbedringer af og i forbindelse med barrierer
EP3961945C0 (en) DECODING METHODS AND APPARATUS
EP3691273C0 (en) DECODING DEVICE AND DECODING METHOD
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3302549T3 (da) Kombinationsbehandling af et anti-CD20-antistof med en Bcl-2-inhibitor og en MDM2-inhibitor
DK3367852T3 (da) Indretning og fremgangsmåde til behandling af levnedsmidler
DK3102218T3 (da) Behandling af topiske og systemiske bakterieinfektioner
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3319609T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer
DK3297651T3 (da) Synergistisk kombination af neuronale levedygtighedsfaktorer og anvendelser deraf